SCHEMBL19660296

SCHEMBL19660296

CC(=O)OCOC(=O)[C@@H](N)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DPP4 P27487 5/20 0.34
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPT P10636 1/20 0.31
PTGS1 P23219 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PGR P06401 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
HTR1A P08908 1/20 0.30
CHRM5 P08912 1/20 0.30
CHRM1 P11229 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRM3 P20309 1/20 0.30
TBXA2R P21731 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577874 0.83 ALOX15 (0.39) ALDH1A1LMNAHSD17B10DPP4MAPT
SCHEMBL15623785 0.78 DPP4 (0.42) ALDH1A1LMNAHSD17B10DPP4MAPT
SCHEMBL23125484 0.77 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL19425739 0.77 SLC7A5 (0.41) ALDH1A1LMNAHSD17B10DPP4MEN1
SCHEMBL8288611 0.77 SLC7A5 (0.41) ALDH1A1LMNAHSD17B10DPP4MEN1
SCHEMBL17833247 0.76 DPP4 (0.33) DPP4
SCHEMBL17833080 0.76 DPP4 (0.33) DPP4
SCHEMBL15574916 0.76 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL15574917 0.76 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10MEN1KMT2A
SCHEMBL8004357 0.76 ALOX15 (0.44) ALDH1A1LMNAHSD17B10DPP4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170342064-A1 COMPOUNDS FOR THE TREATMENT OF CANCER BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342064-A1 COMPOUNDS FOR THE TREATMENT OF CANCER MPST, TK1, BRCA1 ALDH1A1 1557/4885LMNA 1593/4885HSD17B10 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.